Our Services
Medical Information
Helpful Resources
Published on: 9/14/2026
Feeling worse on Cymbalta (duloxetine) does not automatically mean you should stop it, but you should never quit abruptly on your own, because stopping suddenly can trigger discontinuation symptoms such as dizziness, nausea, irritability, brain fog and electric shock sensations. Mild side effects and a temporary dip in mood are common in the first few weeks and often ease, while worsening depression, new or increasing suicidal thoughts, agitation, severe rash or signs of serotonin syndrome are urgent reasons to seek care right away. Several important factors change the answer, including how long you have taken it, your dose, your diagnosis, and whether a slow taper or a switch to another medication is safer, so see below to understand more before making any change.
Because "feeling worse" can mean anything from a passing adjustment period to a serious reaction that needs same day attention, it helps to get a structured read on your specific symptoms first. Take a free, instant, online symptom check to clarify what may be driving how you feel and to plan the right next step with your prescriber.
Last reviewed for medical accuracy: 09/14/2026
Deciding whether to stop taking Cymbalta (duloxetine) can be challenging, especially if you notice feeling worse after starting or increasing your dose. Cymbalta is a commonly prescribed antidepressant and pain reliever, but like all medications, it can cause side effects or temporary mood changes. Here’s what you need to know, based on credible medical guidance, to make a safe, informed decision.
Adjustment period
Activation vs. benefit delay
Dose changes
It’s important to separate medication side effects from a genuine decline in mental health:
Side effects that often improve:
Signs of genuine worsening (contact your doctor):
Each person’s experience is unique. You might discuss a change with your doctor if you:
Keep a symptom diary
Use a trusted symptom checker
Set up a medical review
Avoid self-tapering
Side Effect
| Management Tips
| —
| Nausea | Take with food, split the dose, ginger tea or small, frequent meals
| Headache | Hydrate, rest in a dark room, over-the-counter pain relief (if approved)
| Dizziness | Stand up slowly, avoid driving until you know how it affects you
| Insomnia or fatigue | Maintain consistent sleep schedules, limit caffeine, practice relaxation before bed
Seek emergency care or call your local crisis line if you experience:
Your health and safety come first. Always consult your prescribing clinician before making any changes to your medication regimen.
(References)
* Knotkova H, Pappagallo M. Adjuvant analgesics. Med Clin North Am. 2007 Jan;91(1):113-24. doi: 10.1016/j.mcna.2006.10.007. PMID: 17164107.
* Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J. Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review. Psychother Psychosom. 2018;87(4):195-203. doi: 10.1159/000491524. Epub 2018 Jul 17. PMID: 30016772.
* Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, Kelley MR, Lavino A, Lustberg MB, Paice JA, Schneider BP, Lavoie Smith EM, Smith ML, Smith TJ, Wagner-Johnston N, Hershman DL. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol. 2020 Oct 1;38(28):3325-3348. doi: 10.1200/JCO.20.01399. Epub 2020 Jul 14. PMID: 32663120.
* Zhang S. Chemotherapy-induced peripheral neuropathy and rehabilitation: A review. Semin Oncol. 2021 Jun;48(3):193-207. doi: 10.1053/j.seminoncol.2021.09.004. Epub 2021 Sep 22. PMID: 34607709.
* Kishi T, Ikuta T, Sakuma K, Okuya M, Hatano M, Matsuda Y, Iwata N. Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. Mol Psychiatry. 2023 Jan;28(1):402-409. doi: 10.1038/s41380-022-01824-z. Epub 2022 Oct 17. PMID: 36253442; PMCID: PMC9812779.
* Birkinshaw H, Friedrich CM, Cole P, Eccleston C, Serfaty M, Stewart G, White S, Moore RA, Phillippo D, Pincus T. Antidepressants for pain management in adults with chronic pain: a network meta-analysis. Cochrane Database Syst Rev. 2023 May 10;5(5):CD014682. doi: 10.1002/14651858.CD014682.pub2. Epub 2023 May 10. PMID: 37160297; PMCID: PMC10169288.
* Migliorini F, Maffulli N, Eschweiler J, Baroncini A, Bell A, Colarossi G. Duloxetine for fibromyalgia syndrome: a systematic review and meta-analysis. J Orthop Surg Res. 2023 Jul 17;18(1):504. doi: 10.1186/s13018-023-03995-z. Epub 2023 Jul 17. PMID: 37461044; PMCID: PMC10351165.
* Ma J, Björnsson ES, Chalasani N. The Safe Use of Analgesics in Patients with Cirrhosis: A Narrative Review. Am J Med. 2024 Feb;137(2):99-106. doi: 10.1016/j.amjmed.2023.10.022. Epub 2023 Oct 31. PMID: 37918778.
* Maharty DC, Hines SC, Brown RB. Chronic Low Back Pain in Adults: Evaluation and Management. Am Fam Physician. 2024 Mar;109(3):233-244. PMID: 38574213.
* Birkinshaw H, Friedrich C, Cole P, Eccleston C, Serfaty M, Stewart G, White S, Moore A, Phillippo D, Pincus T. Antidepressants for pain management in adults with chronic pain: a network meta-analysis. Health Technol Assess. 2024 Oct;28(62):1-155. doi: 10.3310/MKRT2948. PMID: 39367772; PMCID: PMC11474957.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.